Department of Oncology, University of Torino, Torino, Italy.
Pathology Division, S. Antonio and Biagio Hospital, Alessandria, Italy.
Int J Cancer. 2020 Jan 1;146(1):192-207. doi: 10.1002/ijc.32419. Epub 2019 Jun 4.
Malignant pleural mesothelioma (MPM) is a tumor with high chemoresistance and poor prognosis. MPM-initiating cells (ICs) are known to be drug resistant, but it is unknown if and how stemness-related pathways determine chemoresistance. Moreover, there are no predictive markers of IC-associated chemoresistance. Aim of this work is to clarify if and by which mechanisms the chemoresistant phenotype of MPM IC was due to specific stemness-related pathways. We generated MPM IC from primary MPM samples and compared the gene expression and chemo-sensitivity profile of IC and differentiated/adherent cells (AC) of the same patient. Compared to AC, IC had upregulated the drug efflux transporter ABCB5 that determined resistance to cisplatin and pemetrexed. ABCB5-knocked-out (KO) IC clones were resensitized to the drugs in vitro and in patient-derived xenografts. ABCB5 was transcriptionally activated by the Wnt/GSK3β/β-catenin/c-myc axis that also increased IL-8 and IL-1β production. IL-8 and IL-1β-KO IC clones reduced the c-myc-driven transcription of ABCB5 and reacquired chemosensitivity. ABCB5-KO clones had lower IL-8 and IL-1β secretion, and c-myc transcriptional activity, suggesting that either Wnt/GSK3β/β-catenin and IL-8/IL-1β signaling drive c-myc-mediated transcription of ABCB5. ABCB5 correlated with lower time-to-progression and overall survival in MPM patients treated with cisplatin and pemetrexed. Our work identified multiple autocrine loops linking stemness pathways and resistance to cisplatin and pemetrexed in MPM IC. ABCB5 may represent a new target to chemosensitize MPM IC and a potential biomarker to predict the response to the first-line chemotherapy in MPM patients.
恶性胸膜间皮瘤(MPM)是一种化疗耐药性高、预后差的肿瘤。已知间皮瘤起始细胞(IC)具有耐药性,但尚不清楚是否以及如何通过与干细胞相关的途径来确定化疗耐药性。此外,目前还没有与 IC 相关的化疗耐药性相关的预测标志物。本研究旨在阐明 MPM-IC 的化疗耐药表型是否以及通过哪些机制归因于特定的与干细胞相关的途径。我们从原发性 MPM 样本中生成 MPM-IC,并比较了同一患者的 IC 和分化/贴壁细胞(AC)的基因表达和化疗敏感性谱。与 AC 相比,IC 上调了药物外排转运蛋白 ABCB5,这决定了对顺铂和培美曲塞的耐药性。ABCB5 敲除(KO)IC 克隆在体外和患者来源的异种移植中对药物重新敏感。ABCB5 被 Wnt/GSK3β/β-catenin/c-myc 轴转录激活,该轴还增加了 IL-8 和 IL-1β 的产生。IL-8 和 IL-1β-KO IC 克隆降低了 c-myc 驱动的 ABCB5 转录,并重新获得了化疗敏感性。ABCB5-KO 克隆的 IL-8 和 IL-1β 分泌和 c-myc 转录活性较低,表明 Wnt/GSK3β/β-catenin 和 IL-8/IL-1β 信号均驱动 c-myc 介导的 ABCB5 转录。ABCB5 与接受顺铂和培美曲塞治疗的 MPM 患者的疾病进展时间和总生存期较短相关。我们的工作确定了多个自分泌环,将干细胞途径与 MPM-IC 对顺铂和培美曲塞的耐药性联系起来。ABCB5 可能代表一种新的化疗增敏靶点,也是预测 MPM 患者对一线化疗反应的潜在生物标志物。
Lung Cancer. 2018-3-26
Proc Natl Acad Sci U S A. 2019-1-18
Cancer Chemother Pharmacol. 2008-4
Cancers (Basel). 2025-3-14
Int J Mol Sci. 2025-3-4
Cancer Drug Resist. 2024-8-7